MSD, a unit of U.S. drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India.
While we wait for the July 15 “on the merits” hearing in India related to the Glenmark v. Merck case (also involving a generic version of sitagliptin, now being sold in India), we confirm from a source with direct knowledge of the matter that the Delhi High Court has granted Merck the same interim relief against Aprica Pharma that it was denied, against Glenmark, back in April.
Case Details:
Delhi High Court: CS(OS) 1236/2013: MERCK SHARP AND DOHME CORPORATION & ANR Vs. APRICA PHARMACEUTICALS PRIVATE LIMITED
Advocate : ANAND AND ANAND, Next Date: 13/08/2013
While we wait for the July 15 “on the merits” hearing in India related to the Glenmark v. Merck case (also involving a generic version of sitagliptin, now being sold in India), we confirm from a source with direct knowledge of the matter that the Delhi High Court has granted Merck the same interim relief against Aprica Pharma that it was denied, against Glenmark, back in April.
Case Details:
Delhi High Court: CS(OS) 1236/2013: MERCK SHARP AND DOHME CORPORATION & ANR Vs. APRICA PHARMACEUTICALS PRIVATE LIMITED
Advocate : ANAND AND ANAND, Next Date: 13/08/2013